Boardroom Alpha
Meeting calendar
XTER · Special meeting · Monday, October 19, 2026

Karman Line Acquisition Corp

2 ballot items.

Shareholders are being asked to approve the Company’s name change to Xterax Corporation II and related constitutional amendments, and to authorize adjournment of the Extraordinary General Meeting if additional proxy solicitation or time is needed.

Market cap
$267M
1Y TSR
—
Board grade
—
Record date
Sep 15, 2026
Filing
DEF 14A
Meeting concluded · Oct 19, 2026

Follow how the vote landed and what changed on Karman Line Acquisition Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot2

  1. 1

    Name Change Proposal

    ManagementBoard: FOR

    Approve, as a special resolution, changing the Company’s name from “Karman Line Acquisition Corp.” to “Xterax Corporation II” and adopting a Second Amended and Restated Memorandum and Articles of Association to reflect the name change.

    More detail

    The proposal asks shareholders to approve a change in the Company’s legal name from Karman Line Acquisition Corp. to Xterax Corporation II. Approval also authorizes adoption of a Second Amended and Restated Memorandum and Articles of Association reflecting the new name. The resolution is structured as a special resolution under Cayman Islands law and requires at least two-thirds of votes cast by the Class A and Class B ordinary shares voting together. The Board is seeking approval because it believes the current name is used by, or closely resembles the names of, other marketplace entities. Management states that this overlap could confuse investors, counterparties and other market participants. It also believes the overlap could hinder the SPAC’s efforts to establish a distinct identity while it pursues an initial business combination. If approved, the Company will file the resolution and amended constitutional documents with the Cayman Islands Registrar of Companies. The ticker symbols and CUSIP numbers for the Company’s securities will not change, and shareholders will not need to exchange existing certificates. The Board unanimously recommends a vote FOR because it considers the name change and related constitutional amendment to be in the best interests of the Company and its shareholders.

  2. 2

    Adjournment Proposal

    ManagementBoard: FOR

    Approve, as an ordinary resolution, adjournment of the Extraordinary General Meeting to a later date or dates, or indefinitely, if additional proxy solicitation or time is needed to obtain approval of the Name Change Proposal or effectuate the Name Change.

    More detail

    The proposal asks shareholders to authorize adjournment of the Extraordinary General Meeting to a later date or dates, or indefinitely. The authority would be available if the vote count shows insufficient support for the Name Change Proposal. It would also be available if the Board determines that additional time is necessary or convenient to effectuate the name change. A principal purpose is to permit further solicitation of proxies from shareholders who have not yet voted. The proposal is separate from the Name Change Proposal and is not conditioned on its approval. Approval requires an ordinary resolution, meaning a simple majority of votes cast by the Class A and Class B ordinary shares voting together. If shareholders reject the proposal, the meeting chair may lack the ability to adjourn the meeting for additional proxy solicitation when the vote is insufficient. The Board views the flexibility as beneficial because it could help secure the votes required for the related special resolution or address implementation timing. The Board unanimously recommends voting FOR the Adjournment Proposal.

Director elections

Nominees on the ballot

Nominee list not yet available for this filing.
Ownership

Top institutional holders

Latest 13F quarter
No 13F holder data available for this ticker.
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Karman Line Acquisition Corp 2026 special meeting?
Karman Line Acquisition Corp (XTER) holds its 2026 special shareholder meeting on Monday, October 19, 2026.
What is the record date for the Karman Line Acquisition Corp 2026 meeting?
The record date for the Karman Line Acquisition Corp 2026 meeting is Tuesday, September 15, 2026. Shareholders of record on or before that date are eligible to vote.
What proposals will shareholders vote on at the Karman Line Acquisition Corp 2026 meeting?
Shareholders will vote on 2 proposals at the Karman Line Acquisition Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer